Enabling a four-fold increase in titer for mAb manufacturing using Syngene’s platform process

Learn how Syngene’s platform approach to mAb manufacturing helped a biopharma company achieve a four-fold increase in titer in less than a year, resulting in improved efficiency and reduced costs.

Author

Latest Blogs

Electrochemical cell design: Turning electron transfer into a practical synthetic tool

Semi-targeted integration in cell line development supports stable clone selection and more predictable biologics development.

What semi-targeted integration changes in biologics development

India as a Global CRDMO Powerhouse: Debunking Quality Myths

Oligonucleotide Analytical Development: Five Hidden Traps and How to Avoid Them

Allometric scaling vs PBPK: when each approach helps in human dose prediction

From PBPK modeling to first-in-human dose: how predictive DMPK can reduce early clinical risk